Helus Pharma Inc. (HELP) Stock Price, Quote & News

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethyla...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 764 8385

Website: www.helus.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

koosbasters Aug. 19 at 6:51 PM

$HELP 20$ soon

0 · Reply

firetypecracker Aug. 19 at 6:31 PM

$HELP Helus Pharma: Buy Rating Reaffirmed as Phase 3 MDD Program Advances; $70 Price Target Maintained Patrick Trucchio has given his Buy rating due to a combination of factors tied to Helus Pharma’s late‑stage asset and corporate developments. The company has fully enrolled its pivotal APPROACH Phase 3 study of HLP003 in major depressive disorder, with clean drug‑drug interaction data that suggest minimal pharmacokinetic risk when used alongside standard antidepressants, reducing a key source of clinical uncertainty. In addition, Helus has strengthened its leadership by appointing Michael Halstead, a seasoned executive with a strong track record in CNS drug commercialization, as CEO, which Trucchio views as an endorsement of the existing trial design and HLP003’s prospects... https://www.tipranks.com/news/ratings/helus-pharma-buy-rating-reaffirmed-as-phase-3-mdd-program-advances-70-price-target-maintained-ratings-news

0 · Reply

finck Aug. 19 at 6:06 PM

$HELP lets go make that run now.

0 · Reply

RkyMtnChi Aug. 19 at 5:38 PM

$HELP https://www.pharmavoice.com/news/helus-pharma-ceo-michael-halstead-psychedelic-drug-pipeline/828108/

0 · Reply

cambruck7 Aug. 19 at 4:24 PM

$HELP

0 · Reply

ChristopherMcC Aug. 19 at 1:58 PM

$HELP two personal friend hires by a Michael. Reminds me of the last two personal friend hires from a Michael. Just exchange the last names and Intracellular for Shire. Lets hope this Michael lasts a lot longer.

0 · Reply

jlcTrader86 Aug. 19 at 1:49 PM

$HELP

0 · Reply

VikaDelic Aug. 19 at 11:14 AM

$HELP $CMPS $DFTX sector will probably run randomly in next few weeks, we’re only 10 weeks from the election and Trump has ibogaine on his mind this week, connect the dots why… it didn’t just pop in his brain, maybe he was briefed on something cross relevant (like the CMPS looming approval) and they reminded him of the ibogaine angle or he remembered the most unusual name? Ask yourself why Trump mentioned psychedelics and the sector went up only 1-2%, this is final accumulation time before the party

2 · Reply

DCcomet Aug. 19 at 10:41 AM

$HELP What's the word on Heidi Overton?

2 · Reply

Marcelline Aug. 19 at 4:14 AM

$HELP Number 5 trending right now

0 · Reply

Helus Pharma appoints Regina Donohue as chief people officer

Aug 18, 2026, 7:30 AM EDT - 1 day ago

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board

Aug 14, 2026, 4:00 PM EDT - 4 days ago

Cybin Earnings release: Q1 2027

Aug 14, 2026, 7:28 AM EDT - 5 days ago

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Aug 12, 2026, 12:00 PM EDT - 7 days ago

Cybin Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-05T14:38:41.000Z - 14 days ago

Helus Pharma appoints Michael Halstead as CEO

Aug 3, 2026, 7:40 AM EDT - 16 days ago

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

2026-07-27T09:20:12.000Z - 23 days ago

Helus Pharma initiated with an Overweight at Wells Fargo

2026-07-21T15:05:31.000Z - 4 weeks ago

Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003

Jul 21, 2026, 7:50 AM EDT - 4 weeks ago

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

2026-07-17T11:10:24.000Z - 4 weeks ago

Helus Pharma price target lowered to $45 from $48 at Guggenheim

ATAI GHRS LLY

2026-07-14T13:41:08.000Z - 5 weeks ago

Helus Pharma price target lowered to $15 from $30 at Alliance Global

2026-07-09T13:50:15.000Z - 5 weeks ago

Psychedelic: Compass Pathways reports six-month data for psilocybin drug

ATAI CMND CMPS DFTX

2026-07-09T10:05:14.000Z - 5 weeks ago

Helus Pharma price target lowered to $70 from $95 at H.C. Wainwright

2026-07-01T10:40:45.000Z - 7 weeks ago

Helus Pharma price target lowered to $42 from $45 at Canaccord

Jun 29, 2026, 7:40 AM EDT - 7 weeks ago

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

Jun 29, 2026, 7:00 AM EDT - 7 weeks ago

Cybin Annual report: Q4 2026

Jun 29, 2026, 7:00 AM EDT - 7 weeks ago

Cybin Earnings release: Q4 2026

Jun 29, 2026, 7:00 AM EDT - 7 weeks ago

Cybin Slides: Corporate presentation

Jun 25, 2026, 9:27 AM EDT - 7 weeks ago

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

2026-06-24T10:35:20.000Z - 2 months ago

Helus Pharma prices 10.31M common shares at $4.85 in public offering

2026-06-24T10:05:22.000Z - 2 months ago

Helus Pharma says enrollment in APPROACH Phase 3 trial ‘progressing as planned’

Jun 24, 2026, 6:01 AM EDT - 2 months ago

Helus Pharma™ Announces US$50 Million Underwritten Offering

Jun 24, 2026, 6:00 AM EDT - 2 months ago

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Cybin Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 11, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference

Jun 4, 2026, 2:35 PM EDT - 2 months ago

Cybin Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Apr 30, 2026, 7:17 PM EDT - 3 months ago

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 30, 2026, 7:30 AM EDT - 3 months ago

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Apr 28, 2026, 7:30 AM EDT - 4 months ago

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 23, 2026, 7:30 AM EDT - 4 months ago

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

Apr 20, 2026, 2:05 PM EDT - 4 months ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS DFTX GHRS

Apr 20, 2026, 8:15 AM EDT - 4 months ago

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Apr 20, 2026, 6:43 AM EDT - 4 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX ENVB GHRS

Apr 16, 2026, 7:30 AM EDT - 4 months ago

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Cybin Slides: Corporate presentation

Mar 12, 2026, 7:30 AM EDT - 5 months ago

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Mar 5, 2026, 7:30 AM EST - 5 months ago

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Mar 5, 2026, 7:30 AM EST - 5 months ago

Cybin Transcript: Study result

Mar 5, 2026, 7:30 AM EST - 5 months ago

Cybin Press release: Study result

Mar 5, 2026, 7:30 AM EST - 5 months ago

Cybin Slides: Study result

Feb 24, 2026, 7:45 AM EST - 6 months ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 17, 2026, 7:30 AM EST - 6 months ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 13, 2026, 12:30 PM EST - 6 months ago

Cybin Earnings release: Q3 2026

Feb 13, 2026, 7:31 AM EST - 6 months ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Dec 30, 2025, 3:33 PM EST - 8 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 19, 2025, 7:00 AM EST - 8 months ago

Cybin Registration statement: Registration Filing

Dec 18, 2025, 12:29 PM EST - 8 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Nov 17, 2025, 7:30 AM EST - 9 months ago

Cybin Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Cybin Earnings Call Transcript: Q2 2026

Nov 13, 2025, 8:00 AM EST - 9 months ago

Cybin Earnings release: Q2 2026

Nov 13, 2025, 7:20 AM EST - 9 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 10 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 10, 2025, 4:30 PM EST - 10 months ago

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:30 AM EST - 10 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 2:00 PM EST - 10 months ago

Cybin Transcript: Future of Health Summit 2025

Nov 5, 2025, 7:30 AM EST - 10 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 10 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 10 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 10 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 11 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 17, 2025, 9:20 AM EDT - 1 year ago

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Cybin Registration statement: Registration Filing

Sep 11, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 11:00 AM EDT - 1 year ago

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:30 AM EDT - 1 year ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 5, 2025, 10:20 AM EDT - 1 year ago

Cybin Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 1 year ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 1 year ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 1 year ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 10:00 AM EDT - 1 year ago

Cybin Transcript: AGM 2025

Aug 13, 2025, 5:30 PM EDT - 1 year ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Cybin Earnings release: Q1 2026

Aug 12, 2025, 2:30 PM EDT - 1 year ago

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Cybin Registration statement: Registration Filing

Jul 17, 2025, 7:30 AM EDT - 1 year ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

koosbasters Aug. 19 at 6:51 PM

$HELP 20$ soon

0 · Reply

firetypecracker Aug. 19 at 6:31 PM

0 · Reply

finck Aug. 19 at 6:06 PM

$HELP lets go make that run now.

0 · Reply

RkyMtnChi Aug. 19 at 5:38 PM

$HELP https://www.pharmavoice.com/news/helus-pharma-ceo-michael-halstead-psychedelic-drug-pipeline/828108/

0 · Reply

cambruck7 Aug. 19 at 4:24 PM

$HELP

0 · Reply

ChristopherMcC Aug. 19 at 1:58 PM

0 · Reply

jlcTrader86 Aug. 19 at 1:49 PM

$HELP

0 · Reply

VikaDelic Aug. 19 at 11:14 AM

2 · Reply

DCcomet Aug. 19 at 10:41 AM

$HELP What's the word on Heidi Overton?

2 · Reply

Marcelline Aug. 19 at 4:14 AM

$HELP Number 5 trending right now

0 · Reply

smushmuffin69 Aug. 19 at 3:55 AM

$HELP this better help me cover my losses in other stocks

0 · Reply

Soulokash Aug. 19 at 3:44 AM

$HELP Its August 18th. The stock price will swing 50 or 60 cents a day. Relax man. We are nowhere close to Q4 yet. Lets see what happens in the next month before having a panic attack. This stock might drop but most likely it creates generational wealth for a lot of people if it hits.

0 · Reply

Ridethesqueeze Aug. 19 at 3:14 AM

$HELP I do hate to say it, but I am concerned that HLP003 Phase III results are very likely to fall short of expectations (even though the data will be great), and there will be a strong sell-off just like we saw with HLP004. I hope I'm wrong but can't ignore my spider senses.

1 · Reply

Mastacash Aug. 19 at 2:01 AM

$HELP still waiting for the momentum bros to come piling in, now that their data centre trades have gone to shit. My conservative target is $17 by q4, that’s a billion dollar market cap, more if successful obviously, I said years ago I think this programs can be worth 2 billion, that’s $37.

0 · Reply

MarkM Aug. 19 at 1:40 AM

$HELP What are the board's takes on Dr. Heidi Overton taking over as FDA commissioner? Positive for the psychedelic therapy community or more cautious like commissioners in the past?

0 · Reply

Solomonwisdom7 Aug. 18 at 11:45 PM

$HELP It’s hard to tell how the share price is going to move over the next 2 months when there isn’t going to be much high value news until top line phase 3 results. I asked ChatGTP: AI 60-day scenario Scenario Approx. probability 60-day price Bull case 25% $15–$20+ Base case 50% $10–$14 Bear case 25% $6–$9 Based on this AI analysis I think it will probably drop to $10 ish for a short time. But if those top line results in 8-12 weeks don’t live up to expectations it will drop below $5.

1 · Reply

RuddyRolls Aug. 18 at 10:13 PM

$HELP @Solomonwisdom7 it may settle at 10-11 but I think far more likely to run to 15-22, perhaps as much as 25, pre phase 3 data simply because of the disparity between it and the mkt cap of peers. And due to its sheer momentum - it's very very strong. I know - I called the bottom at 3.80 and have watched it closely since while collecting large. Yes, there are downside risks At The Point the phase 3 data actually lands (perhaps downside odds of 30-40 per cent likelihood if 1) weak data or 2) middling data - that does not meet mkt expectations). And again on CMPS approval decision (80 per cent likely approval). But on strong to knock out data it should rerate to peers at around $1.5-$3B (or more on the knock out end) giving a superb 2-4x or greater move - with excellent 60-70 per cent odds. I'm not sure how large my position will be going in to the data release or the mix of it (shares/ options), but as I am in heavy I naturally am already hedged. GL

1 · Reply